

Sayed Hashemi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1001315/publications.pdf>

Version: 2024-02-01

9
papers

237
citations

1478505

6
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

356
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultralocal” Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1081-1089.	1.1	176
2	Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. <i>Lung Cancer</i> , 2018, 124, 130-134.	2.0	12
3	Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9593-9593.	1.6	12
4	Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 152, 149-156.	2.0	11
5	Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9112-9112.	1.6	9
6	Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9042-9042.	1.6	8
7	The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100195.	1.1	4
8	Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9065-9065.	1.6	4
9	Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9066-9066.	1.6	1